Cyclerion Therapeuticsincis A Clinical Stage Biopharmaceutical Company Based In Cambridgemassachusettsfocused On Developing Innovative Treatments For Serious Diseasesparticularly Central Nervous Systemcnsdisorders And Rare Diseasesfounded In 2018Cyclerion Aims To Advance A New Generation Of Soluble Guanylate Cyclasesgcstimulators That Target Specific Tissues Relevant To The Diseases They Address The Company S Product Pipeline Features Several Sgc Stimulators At Various Development Stagesolinciguat Is In Phase 2 Clinical Trials For Sickle Cell Disease And Cardiovascular Conditionspraliciguat Is Being Developed For Rare Kidney Diseasesincluding Diabetic Nephropathyunder A License Agreement With Akebiaadditionallycy6463 Is Targeting Mitochondrial Diseases And Is Currently In Phase 2 Trialscyclerion Also Engages In Research And Development Collaborations To Further Its Pipeline Programs
